Recruiting

Cannabis

Sponsor:

Scot Remick

Code:

NCT07089225

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This study is being done because there is a significant lack of data on the use of cannabis amongst cancer patients. The investigators believe that the collection of this data will help researchers and clinicians better understand the needs and the impact of cannabis use in this specific patient population.

Conditions

Cancer

Study ID

NCT07089225

Start date

Oct 17, 2025

Status verified date

Oct, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

May 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must be 18 years of age or older and able to give verbal informed consent to participate.
  • Patients must be able to speak, read and understand English.
  • Patients must report use of cannabis at time of study participation.
  • Patients must have access to internet and ability to download Releaf™ App (MoreBetter, Ltd.) to a smartphone or tablet and must use Releaf™ App (MoreBetter, Ltd.) for cannabis journaling.
  • Patients must be able to send and receive text messages, and be able to interact with web-pages on smartphone or tablet.
  • There are 2 scenarios that patients are eligible for participation, and are listed below:

1. Patients must have a cancer diagnosis for which they are receiving active therapy defined as follows:

  • Surgery - must be within a 30-day pre- and/or post-operative (peri-operative) window if single modality of care. Patients must be 18 years of age or older and able to give verbal informed consent to participate.
  • Radiation - must be within a 30-day pre- (simulation planning phase) and/or post-radiation window if single modality of care.
  • Any anticancer systemic therapy including hormonal, biologic, targeted, and/or cytotoxic chemotherapy. Understandably, numerous patients recruited under surgery and/or radiation will receive systemic therapy as part of combined modality therapy, which is permissible. Regardless, all details regarding cancer diagnosis, stage, and treatment will be collected from the EMR, which will be detailed in the informed consent document.
2. Any patient in follow-up by their primary oncology care provider and/or AYA and cardio-oncology survivorship clinic(s).
  • All patients must be treated within the MHCCN thus ensuring access to clinical data in our system-wide EMR (Epic).
  • Patients must obtain their cannabis either from a medical-use store, adult-use (recreational) store or both. Patients must obtain cannabis ONLY from medical/recreational stores. Illicit (or homegrown) sources are strictly prohibited.

Study Design

Enrollment

45 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Cannabis Use [ Time Frame: Enrollment + 6 months ]

Central Contacts and Locations

Central contacts

Clinical Research Coodinator

207-550-1265ntro@mainehealth.org

Research Program Manager

ntro@mainehealth.org

Locations

MaineHealth Cancer Care

Recruiting

Scarborough, Maine, United States, 04074

Contacts

Clinical Trials Manager

256-541-1068ntro@mainehealth.org

Principal Investigator:

Scot Remick, MD

More Information

Sponsor

Scot Remick

Last update posted

Oct 22, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Scot Remick on 2026-10-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.